Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study... | August 12, 2022

Related Keywords

California ,United States ,South San Francisco ,Washington School ,American ,Laurence Watts ,Hugh Young Rienhoff Jr ,Joseph Hiatt ,Rafael Santana Davila ,Company Nasdaq ,Linkedin ,National Cancer Institute ,Canale Communications ,European Hematology Association ,Research Development Rd Expenses ,American Society Of Hematology ,Facebook ,Globenewswire Inc ,Imago Biosciences Inc ,Fred Hutchinson Cancer Center Hutch ,Washington School Of Medicine ,Endpoints For The Company Planned Phase ,Gilmartin Group ,European Medicines Agency ,Ongoing Phase ,Essential Thrombocythemia ,Hematology Association ,Advanced Myelofibrosis Presented ,Participant Dosed ,Investigator Sponsored Phase ,Small Cell ,Outcomes Assessment ,Patient Reported Outcome ,Planned Phase ,Young Rienhoff ,Chief Executive Officer ,Positive Data ,Total Symptom Score ,Advanced Myelofibrosis ,First Participant Dosed ,Investigator Sponsored Study ,Hutchinson Cancer Center ,Cancer Institute ,Annual Meeting ,Cash Equivalents ,Short Term Investments ,Fast Track Designation ,Medicines Agency ,Orphan Designation ,San Francisco ,Private Securities Litigation Reform Act ,Fast Track ,Good Manufacturing Practice ,Annual Report ,Consolidated Statements ,Imago Biosciences ,Nc Stock Exchange ,News ,Information ,Press Release ,Positive ,Data ,Rom ,The ,Ngoing ,Hase , ,Study ,F ,Omedemstat ,N ,Essential ,Hrombocythemia ,Resented ,It ,European ,Hematology ,Association ,Meeting ,022 , Imgo Us45250k1079 ,